China: Biotechnology Wuxi STA and Bio Lingus Collaborate for Sublingual Delivery
Both the companies have signed an exclusive technology and marketing collaboration for sublingual delivery. The move aims to further integrate the advantages of Wuxi STA drug product services and expedite the development of Bio Lingus’ pipeline and usage of sublingual delivery technology.
Shanghai/China – STA Pharmaceutical (Wuxi STA), a subsidiary of Wuxi App Tec – and Bio Lingus, a Swiss biotech company, have recently announced they have formed an exclusive technology and marketing collaboration for sublingual delivery.
Under the terms of the collaboration, Wuxi STA will have exclusive access to Bio Lingus’ technology for sublingual and buccal delivery in the contract development and manufacturing organisation sector. Bio Lingus has developed a novel platform – with patents secured in major countries around the world – to stabilise and deliver sublingually (orally under the tongue) drug targets including small molecules, peptides and proteins, that are currently administered to patients via injection.
The collaboration will help further integrate the advantages of Wuxi STA drug product services and expedite the development of Bio Lingus’ pipeline and usage of sublingual delivery technology.
In 2017, Wuxi STA merged with Wuxi App Tec’s Pharmaceutical Development Services unit, realising a seamless integration of the entire chemistry, manufacturing and controls supply chain. Over the past year, two new commercial drug product facilities – in Shanghai and Wuxi city, Jiangsu province – have come into operation, enabling Wuxi STA to support solid dosage drug development from preclinical to commercial, with several phase III and commercial drug product projects underway. The newly introduced sublingual delivery technology will further deepen the scale of solid dosage drug capabilities in Wuxi STA, providing customers with more flexible, diverse and advanced solutions.